TY - JOUR
T1 - Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
AU - Toubhans, Benoit
AU - Gazze, Salvatore Andrea
AU - Bissardon, Caroline
AU - Bohic, Sylvain
AU - Gourlan, Alexandra T.
AU - Gonzalez, Deyarina
AU - Charlet, Laurent
AU - Conlan, R. Steven
AU - Francis, Lewis W.
N1 - Funding Information:
This project received support from the Welsh Government ERDF SMART Expertise grant RISE (2017/COL/001), the Medical Research Council UK Confidence in Concept grant (MC_PC_19053) and the Institut National de la Santé et de la Recherche Médicale , France, grant SEDMAC (PC201607).
Funding Information:
This project received support from the Welsh Government ERDF SMART Expertise grant RISE (2017/COL/001), the Medical Research Council UK Confidence in Concept grant (MC_PC_19053) and the Institut National de la Sant? et de la Recherche M?dicale, France, grant SEDMAC (PC201607). Benoit Toubhans received a scholarship co-funded by the Universit? Grenoble Alpes and Swansea University.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/10
Y1 - 2020/10
N2 - High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show any chemotherapeutic value of selenium at safe and tolerated doses (<90 μg/day). To enable the successful exploitation of selenium for cancer treatment, we evaluated inorganic selenium nanoparticles (SeNP), and found them effective in inhibiting ovarian cancer cell growth. In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity. The two cell types displayed contrasting nanomechanical responses to SeNPs, with decreased surface roughness and membrane stiffness, characteristics of OVCAR-3 cell death. In SKOV-3, cell membrane surface roughness and stiffness increased, both properties associated with decreased metastatic potential. The beneficial effects of SeNPs on ovarian cancer cell death appear cell type dependent, and due to their low in vivo toxicity offer an exciting opportunity for future cancer treatment.
AB - High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show any chemotherapeutic value of selenium at safe and tolerated doses (<90 μg/day). To enable the successful exploitation of selenium for cancer treatment, we evaluated inorganic selenium nanoparticles (SeNP), and found them effective in inhibiting ovarian cancer cell growth. In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity. The two cell types displayed contrasting nanomechanical responses to SeNPs, with decreased surface roughness and membrane stiffness, characteristics of OVCAR-3 cell death. In SKOV-3, cell membrane surface roughness and stiffness increased, both properties associated with decreased metastatic potential. The beneficial effects of SeNPs on ovarian cancer cell death appear cell type dependent, and due to their low in vivo toxicity offer an exciting opportunity for future cancer treatment.
KW - Metastasis
KW - Nanomechanics
KW - Nanoparticles
KW - Ovarian Cancer
KW - Selenium
UR - http://www.scopus.com/inward/record.url?scp=85088747567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088747567&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2020.102258
DO - 10.1016/j.nano.2020.102258
M3 - Article
C2 - 32615338
AN - SCOPUS:85088747567
VL - 29
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
SN - 1549-9634
M1 - 102258
ER -